Indicator Explainer
Aldosterone
A mineralocorticoid hormone produced by aldosterone synthase (CYP11B2) in the zona glomerulosa of the adrenal cortex. Aldosterone binds to mineralocorticoid receptors (MR; NR3C2) and MR-aldosterone complexes regulate the expression of genes involved in the retention of sodium, the secretion of potassium, and water reabsorption, all of which may result increased blood pressure.
This page explains what the indicator is and how results are interpreted in general terms. Reference ranges depend on the laboratory, the method, and your own situation — no single “normal value” applies to everyone. This page is health information, not a diagnosis. For symptoms, treatment, or urgent concerns, contact a healthcare professional.
When it is tested
Source: National Cancer Institute, NCI Thesaurus 26.09d, C219. NCI definition, reproduced without modification under CC BY 4.0. Source identity and definition checked automatically on 2026-10-18. No individual clinical interpretation or human reviewer is asserted.
Reading results
Reference intervals and interpretation depend on the laboratory, specimen, method and clinical context. This source definition is educational information; it does not establish a diagnosis, product approval or suitability for an individual.
Also Known As
References
- NCI Thesaurus 26.09d — Aldosterone (C219)
- Source: National Cancer Institute, NCI Thesaurus 26.09d, C219. NCI definition, reproduced without modification under CC BY 4.0.
- Genetic Association of Aldosterone Synthase Inhibition With Cardiac Structure, Function, and Heart Failure. — JACC Heart Fail, 2026-10-07 (PMID 42853164; literature)
- Aldosterone-producing adrenocortical carcinoma presenting with severe, rapidly progressive hypokalemia: a case report and literature review. — Endocr J, 2026-10-02 (PMID 42830519; literature)
- Integrated morphological and transcriptomic analysis of bone disorders in aldosterone-salt hypertension. — Hypertens Res, 2026-10-02 (PMID 42827115; literature)
- Aldosterone synthase inhibitors: biological rationale, mechanism of action, and results of clinical trials. — Am J Hypertens, 2026-10-01 (PMID 42847230; literature)
- Aldosterone synthase inhibitors may alter how primary care treats hypertension. — Am J Hypertens, 2026-10-01 (PMID 42847228; literature)
- Aldosterone-mineralocorticoid receptor signaling and residual cardiorenal risk in type 2 diabetes. — Acta Diabetol, 2026-10-14 (PMID 42873316; literature)
- Coexisting adrenal hemangioma and aldosterone-producing micronodule presented as adrenal incidentaloma. — JCEM Case Rep, 2026-10-13 (PMID 42871030; literature)
- The AGT M235T variant and renin-angiotensin-aldosterone system parameters in a predominantly hypertensive elderly black South African cohort: a hypothesis-generating descriptive case series. — Mol Biol Rep, 2026-10-23 (PMID 42909728; literature)
- Beyond Conventional Antihypertensives: RNA Interference, Endothelin Antagonism, and Aldosterone-Synthase Inhibition in the Current Therapeutic Landscape. — Am J Cardiovasc Drugs, 2026-10-21 (PMID 42907726; literature)
- KLHL20 protects against aldosterone-induced cardiomyocyte cuproptosis by promoting ubiquitination-mediated MR degradation. — Redox Biol, 2026-10-22 (PMID 42945624; literature)
- Effects of Aldosterone Synthase Inhibitor Baxdrostat on Albuminuria in CKD and Uncontrolled Hypertension. — Clin J Am Soc Nephrol, 2026-10-21 (PMID 42905977; literature)